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Conclusion: PTA of femoropopliteal arterial disease using a DEB resulted in consistent
clinical improvement across multiple endpoints with a very low rate of stenting.
TCT-581
Drug Eluting Balloon For Below The Knee Angioplasty Evaluation: The
DEBATE BTK Study
Francesco Liistro1, Paolo Angioli1, Simone Grotti1, Filippo Turini1, Kenneth Ducci1,
Giorgio Ventoruzzo1, Lucia Ricci2, Giovanni Falsini1, Guido Bellandi1, Leonardo
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Background: Drug-eluting balloon showed positive results in terms of restenosis
reduction in peripheral intervention (PTA). The aim of the study is to investigate in a
randomized fashion the efficacy and safety of Paclitaxel-eluting balloon (PEB) (In.Pact
Amphirion, Invatec, Brescia, Italy) versus non drug-eluting balloon (NEB) (Amphirion
deep, Invatec, Brescia, Italy) in diabetic patients with Critical Limb Ischemia (CLI)
undergoing PTA of below-the-knee (BTK) vessels.
Methods: The study, randomized, single center, planned to enroll 150 BTK lesions,
75 lesions in PEB and 75 in NEB group, assuming the 50% absolute reduction of 1-
Year angiographic restenosis of the culprit lesion, the primary endpoint, in the PEB
group.
Results: At the moment, 84 patients with 110 lesions treated are enrolled in the study
and 1-year follow-up is available for 66 lesions in 51 patients, 30 lesions in the PEB
and 36 lesions in the conventional balloon group. No significant differences were
observed in terms of Rutherford Class, clinical and procedural characteristics among
the two groups. Mean age was 71±19 years in PEB vs 77±10 years in NEB (p=0.09),
lesion length 107±76mm vs 128±68mm respectively (p=0.2), occlusions in 82% vs
83% (p=0.9) respectively, sub-intimal recanalization in 12.1% vs 14.5% respectively
(p=0.5). At 1 year, death occurred in 8(10%) of the enrolled patients, 3 in PEB and 5
in NEB. Restenosis, assessed by angiography in 53 lesions (83% in PEB vs 77% in
NEB, p=0.2) and by Duplex Ultrasound in 10 lesions, occurred in 9(27%) PEB vs
23(63%) NEB lesions (p=0.01). Re-occlusion was present in 6(19%)PEB vs
17(44%)NEB lesions (p=0.02). No Major amputation occurred.
Conclusion: By provisional study results, PEB seems to provide better results in terms
of 1-year restenosis compared to NEB in the treatment of BTK lesions in CLI patients.
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Endovascular Therapy of Common Femoral Arterial Disease
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Background: Common femoral endarterectomy is regarded as the standard
revascularization strategy for the treatment of common femoral artery (CFA) disease.
The availability of a variety of endovascular tools has resulted in an increased number
of patients with CFA disease being treated using an endovascular strategy. We sought
to evaluate patient- and procedure-related outcomes in a contemporary series of patients
treated for CFA disease using an endovascular strategy.
Methods: All patients with obstructive CFA disease who were treated using
endovascular therapy were identified from a prospective database. Baseline patient
characteristics, anatomic details, procedural data, and clinical outcomes were assessed.
Kaplan-Meier (KM) curves for mortality, amputation-free survival, and primary and
secondary patency were generated.
Results: Between 2006 and 2011, 30 patients underwent 31 CFA procedures. The
primary etiology of CFA obstruction was atherosclerosis (58%), access-site
complication (32%), and thromboembolism (10%). Patients presented with severe
claudication (60%), critical limb ischemia (13%) or acute limb ischemia (27%). The
procedure was technically successful in 90% of cases, with all failures occurring in
patients with occlusive atherosclerosis of the CFA. Major procedural complications
occurred in 7 procedures (23%). There was no procedural mortality. The KM estimate
of survival and amputation-free survival at one-year was 96% [Standard Error
(SE)±4%] and 96% [SE±4%], respectively. In those patients who had a successful
revascularization, the one year estimate for primary and secondary patency was 88%
[SE±6%] and 92% [SE±5%], respectively. There was a non-significant trend (p=0.08)
towards worse patency in patients treated for atherosclerotic disease compared to those
with access site-related complications and thromboembolic disease.
Conclusion: Endovascular therapy for CFA obstruction is associated with a high rate
of acute technical success Primary patency in the cohort treated for access site-related
complications and thromboembolic disease is excellent. Surgical repair of
atherosclerotic disease in the CFA remains the gold standard.
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Pathologic Features of Atherosclerotic Plaques Retrieved by Excision and
Relevant Biomarkers for the Risk Stratification of Peripheral Artery Disease
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Background: Despite the progress in endovascular treatment for peripheral artery
disease (PAD), the long-term patency rate is still suboptimal. Atherosclerotic plaque
characteristics may be predictive of future events in patients with PAD; however,
morphological plaque features and biomarkers for the risk stratification have not been
reported.
Methods: The current sub-study was conducted as part of the DEFINITIVE LE study,
where excised plaque using the SilverHawk® or TurboHawk™ Peripheral Plaque
Excision Systems (Covidien/ev3, Plymouth, MN) from 113 de novo lesions located in
the superficial femoral artery of 92 patients with claudication were evaluated.
Immunohistochemistry was performed for macrophages (CD68, CD163, CD206), T-
lymphocytes (CD3), HLA-DR, red blood cells (glycophorin A), endothelial cells (ulex),
smooth muscle cells (HHF), Toll-like receptor 4, RAGE and ENRAGE, which were
all graded semi-quantitatively. In addition, RNA and protein profiling were performed
in 20 selected cases where a total of 90 genes and 15 proteins were evaluated.
Results: Histology showed either acute or organizing thrombus in 27 patients (29%).
Patients with thrombus had significantly higher CD163, HLA-DR, and glycophorin A
expression (p=0.01, p=0.02 and p=0.01, respectively) as well as trends toward higher
CD68 and CD206 than those without thrombus. Thrombotic cases also showed
increased expression of numerous inflammatory genes such as TNF, IL-8 and
chemokines (CCL17, 26, CXCL1, 3, and 6) as well as increased levels of several
inflammatory proteins including IL-6 and IL-8. Primary patency data at 6 month was
available in 63 patients where patients with thrombus (n=17, 27%) had a significantly
lower patency rate than those without thrombus (59% [10/17] vs. 87% [40/46],
p=0.014).
Conclusion: The current preliminary analyses reveal that peripheral atherosclerotic
plaques characterized by thrombus are associated with increased expression of several
inflammatory markers and worse clinical outcome following endovascular treatment
compared to patients without thrombus.
TCT-584
Para Millennium High Risk AAA saga: A clinical dilemma but is not a major
concern for the endovascular specialist!
Niamh Hynes2, 1, Sherif Sultan1, 2
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Background: Between 1996 and 2009, of 2868 patients referred with AAA disease,
575 have had AAA repair, performed by one specialist vascular team and two general
surgery teams.
Methods: From 1996-2009 our mean patient age has risen by an average of 0.5% per
annum from 71years in 1996 to 78years in 2009 (p=0.023). There has been a
concomitant significant rise in SVS co-morbidity score (P<0.001), Kertai-probability
index (P<0.01), SVS anatomical score (P<0.01) and the Australasian Endovascular
Aneurysm Repair Risk Assessment (ERA) Model (P<0.05) when comparing 1998 to
2009.
Results: The percentage of endovascular repairs has increased from 0 to 91% and
despite an increase in complexity and a percentage increase of Pararenal repair of <1%
in 1996 to 31% in 2009, there has been a consistent drop in peri-operative mortality
and morbidity rates. Elective operative mortality prior to the establishment of a
specialist deliberate practice volume centre and prior to the introduction of
endovascular techniques in 2002 was 15.7% per annum compared to 1.8% since 2002
(P<0.0001) Freedom from Major adverse events (MACE) has increased over the last
decade from 28% to 78% (p=0.0009, h=0.32 [95%CI=0.17 to 0.61]). Cox proportional
Hazards Ratio showed that age, gender, SVS co-morbidity score, Kertai-probability
index, SVS anatomical score and ERA Model score did not influence 5-year aneurysm
related survival or freedom from MACE.
Conclusion: Procedural innovation, minimally invasive technologies and enhanced
understanding of the management of high-risk factors have led to substantial upturn
in aneurysm survival rates and a profound recuperation of both quality of life and cost-
B157
P
O
S
T
E
R
S
www.JACC.TCTAbstracts2011
JACC Vol 58/20/Suppl B  |  November 7-11, 2011  |  TCT Abstracts/POSTER/Peripheral Vascular Intervention (non carotid, non neurovascular)
